An organ-sparing approach via active surveillance shows promise for oesophageal cancer patients achieving complete clinical response after neoadjuvant therapy. Trials validate a comprehensive diagnostic strategy while early results suggest comparable survival rates and improved quality of life versus immediate surgery. Despite concerns over delayed interventions upon recurrence, data indicate no significant compromise in surgical outcomes. Ongoing studies will refine protocols, explore immunotherapy, and enhance assessment techniques for broader implementation of this strategy.
Review by Pittacolo M, Khoma O (…) Wijnhoven BPL et 2 al. in Dig Surg
© 2025 The Author(s). Published by S. Karger AG, Basel.